VIDO-InterVac is among the first labs in the world to have a vaccine candidate in animal testing
As the COVID-19 outbreak continues to rapidly evolve, the drive toward a vaccine to combat this daunting threat is picking up the pace.
Among those leading the charge is the University of Saskatchewan’s Vaccine and Infectious Disease Organization – International Vaccine Centre (VIDO-InterVac), one of the largest and most advanced infectious disease research facilities in the world, the recent recipient of $23.3 million in support from a newly established national fund for COVID-19 health research.
“This new federal funding recognizes that VIDO-InterVac is at the forefront of global efforts to develop a vaccine for COVID-19 and other infectious disease threats,” says University of Saskatchewan Vice-President of Research Karen Chad. “This is critical work at VIDO-InterVac that will help protect the health and safety of all Canadians, as well as people around the world.”